



You are cordially invited to a symposium on Natera's innovations in circulating tumor DNA for solid tumors.

The Symposium will be held during the XI Congress of Oncologists and Radiologists of CIS and Eurasia 2020

Speaker:

Dr. Alexey Aleshin, M.D., M.B.A.
Senior Medical Director of Oncology,
Natera, Inc

Topic:

A ctDNA assay for remote monitoring and risk stratification of CRC patients

Please send your questions, comments and feedback to: ggaynullina@natera.com

Date:

Saturday
April 25th, 2020

Time:

13:00

Location:

Congress on Thoracoabdominal Oncology M.Z. Segal:
colorectal cancer

In this webinar, attendees will discover:

1. Signatera is a personalized, tumor-informed circulating-tumor DNA (ctDNA) test that can detect the presence of molecular residual disease, and serve as a surveillance tool to assess treatment efficacy or recurrent disease
2. Clinical applications of Signatera in colorectal cancer.
3. Applications for remote cancer monitoring during the COVID-19 crisis to identify patients with lower risk of disease recurrence who may reasonably delay a scheduled surveillance test or chemotherapy